TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 30-day ischemic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day non-CABG-related PLATO major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Inflammation Score (OIS)
Endpoint domain: Adverse events/effects
Primary endpoint: RMDQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: overall cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: skin telangiectasia
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen uptake at the end of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked in 6 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentrations of F‐ara‐A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration‐time curve from 0‐24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of F‐ara‐A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum level of u-LTE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in 24 h systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients meeting 24 h ABPM targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Secondary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection rate in patients with prostate < 40 cc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced drinking at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection from symptomatic DENV3 illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of hives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of largest hive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fissure healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without major neurological abnormality
Endpoint domain: Mortality/survival
Primary endpoint: improvement in tooth color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked to excellent improvement in atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent improvement in Eczema Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percent reduction in pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain management during dressing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction score of the wound therapist and children's parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LM-related progression-free survival (LM-PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional Recurrence-Free Survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: plasma total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular events (CVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Other deaths (OD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fentanyl-induced coughing
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with cosmetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GI score = 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of BoP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score <= 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical status normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT scan lesions disappeared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAR (Survival After Recurrence)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage volume of filling material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage volume of voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: louse-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in drug use for UAP management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median pain score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total epidural analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Atrial fibrillation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early pericardial effusion prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delayed pericardial tamponade prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee Society Score (KSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compression forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response rate for A/H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean antibody titers for A/H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of children achieving protective antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of recommended workups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants in the low risk category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medication adherence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean sensor glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent sensor glucose values >180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of HC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) of HC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicted plasma HM concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of TMS-induced activation of the motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation of limbic regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean number of units of allogeneic blood transfused in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amino acid clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete tumor regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Transient oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in pupae per person index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceptions of organizational commitment to employee health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumbar spine and femoral neck BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of elevated uric acid
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of 4-6-h postdose serum calcium >10.6 mg/dl
Endpoint domain: Adverse events/effects
Primary endpoint: reduced total gastric residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduced incidence of gastric residual volume >150 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduced incidence of intolerance of enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of LCP
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to complete miscarriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extubation failure
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving satisfactory analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of plasma inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased monocyte HLA-DR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Minimum alveolar concentration (MAC) of sevoflurane for LMA insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 years survival figures
Endpoint domain: Mortality/survival
Primary endpoint: incidence of overall rectal complications
Endpoint domain: Adverse events/effects
Primary endpoint: CFUs/ft(3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Very poor sleep quality (PSQI >10)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Short sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV-RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of HCC
Endpoint domain: Mortality/survival
Primary endpoint: mean symptom-medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Bet v 1 specific IgG4 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in tic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to help
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sympathy for a student with bulimic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete heartburn relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nocturnal heartburn relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint of all-cause death, cardiac transplantation, and hospitalization due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Acid-base status derangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velopharyngeal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean QALYs gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: healthcare costs over one year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: C-reactive protein normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-prandial blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastric motility (MMC phase II and III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 5 year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: cause specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Total and hyperactivity-impulsivity subscales of the Parent ADHD Rating Scale-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Distress Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent change in fibrous cap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in plaque microvessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24/7 compliance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of coughing episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Viral load less than 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load less than 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periosteal diameter increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum BAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglyceride plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial carbon dioxide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: L-SRS ratings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Menstrual cycle regularity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting Metabolic Rate (RMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory parameters (VCO2, VE, respiratory rate, RER, heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Boredom (Boredom Evaluation Scale - BES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stain removal effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Potentially avoidable hospitalizations (PAHs)
Endpoint domain: Mortality/survival
Primary endpoint: LV GLS normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TAPSE improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV GLS normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of suboptimal drug treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inappropriate drugs per person
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of missing drugs per person
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Granulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients achieving HIV‐1 RNA level <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving HIV‐1 RNA level <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure before week 48
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative total blood drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for future colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy (non-inferiority)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of urethral stricture
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet reactivity units (PRUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean IOP reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean change in MD from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in number of significant points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %carbOC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Higher lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: repair integrity (retears)
Endpoint domain: Adverse events/effects
Primary endpoint: activity of factor VII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: protein C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: endogenous thrombin potential-based activated protein C resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak values of GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Survey completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic test accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: functional status improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduction in caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: mean breath hydrogen area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 30-day complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6-week abstinence rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resistance to displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Displacement at various loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ease of use of the Glidescope
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nonhemorrhagic CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: verified ischemic stroke or TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes